688606 奥泰生物
已收盘 11-13 15:00:00
资讯
新帖
简况
股市必读:奥泰生物新发布《关于召开2026年第三次临时股东会的通知》
证券之星 · 11-09
股市必读:奥泰生物新发布《关于召开2026年第三次临时股东会的通知》
奥泰生物(688606)披露董事会换届选举议案,11月06日股价下跌0.86%
证券之星 · 11-06
奥泰生物(688606)披露董事会换届选举议案,11月06日股价下跌0.86%
奥泰生物(688606)11月2日主力资金净卖出211.01万元
证券之星 · 11-03
奥泰生物(688606)11月2日主力资金净卖出211.01万元
奥泰生物(688606)2026年三季报简析:净利润同比下降56.3%,三费占比上升明显
证券之星 · 11-01
奥泰生物(688606)2026年三季报简析:净利润同比下降56.3%,三费占比上升明显
奥泰生物(688606)披露2026年第三季度报告,10月30日股价下跌2.18%
证券之星 · 10-30
奥泰生物(688606)披露2026年第三季度报告,10月30日股价下跌2.18%
奥泰生物(688606.SH)发布前三季度业绩,归母净利润8295万元,同比下降56.30%
智通财经 · 10-30
奥泰生物(688606.SH)发布前三季度业绩,归母净利润8295万元,同比下降56.30%
奥泰生物(688606)10月21日主力资金净卖出56.18万元
证券之星 · 10-22
奥泰生物(688606)10月21日主力资金净卖出56.18万元
股市必读:奥泰生物新发布《2026年第二次临时股东会会议资料》
证券之星 · 09-07
股市必读:奥泰生物新发布《2026年第二次临时股东会会议资料》
每周股票复盘:奥泰生物(688606)拟用3518.52万元补流
证券之星 · 09-06
每周股票复盘:奥泰生物(688606)拟用3518.52万元补流
奥泰生物净利连降1年半 2021上市超募12亿申万宏源保荐
中金财经 · 09-04
奥泰生物净利连降1年半 2021上市超募12亿申万宏源保荐
股市必读:奥泰生物新发布《2026年第二次临时股东会会议资料》
证券之星 · 09-04
股市必读:奥泰生物新发布《2026年第二次临时股东会会议资料》
奥泰生物(688606)2026年中报简析:净利润同比下降61.48%,三费占比上升明显
证券之星 · 08-30
奥泰生物(688606)2026年中报简析:净利润同比下降61.48%,三费占比上升明显
奥泰生物(688606)披露董事和高级管理人员薪酬管理制度,8月28日股价上涨0.46%
证券之星 · 08-28
奥泰生物(688606)披露董事和高级管理人员薪酬管理制度,8月28日股价上涨0.46%
图解奥泰生物中报:第二季度单季净利润同比下降55.58%
证券之星 · 08-28
图解奥泰生物中报:第二季度单季净利润同比下降55.58%
奥泰生物(688606)6月30日股东户数0.56万户,较上期增加3.81%
证券之星 · 08-28
奥泰生物(688606)6月30日股东户数0.56万户,较上期增加3.81%
每周股票复盘:奥泰生物(688606)回购362万股已注销
证券之星 · 08-16
每周股票复盘:奥泰生物(688606)回购362万股已注销
股市必读:奥泰生物新发布《关于股份回购实施结果暨股份变动的公告》
证券之星 · 08-14
股市必读:奥泰生物新发布《关于股份回购实施结果暨股份变动的公告》
奥泰生物(688606)披露股份回购实施结果暨股份变动公告,8月12日股价下跌1.62%
证券之星 · 08-12
奥泰生物(688606)披露股份回购实施结果暨股份变动公告,8月12日股价下跌1.62%
奥泰生物(688606)披露股份回购进展公告,8月3日股价上涨1.46%
证券之星 · 08-03
奥泰生物(688606)披露股份回购进展公告,8月3日股价上涨1.46%
每周股票复盘:奥泰生物(688606)回购金额达1.84亿元,占总股本4.18%
证券之星 · 08-02
每周股票复盘:奥泰生物(688606)回购金额达1.84亿元,占总股本4.18%
暂无数据
公司概况
公司名称:
杭州奥泰生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2021-03-25
主营业务:
杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产与销售。公司的主要产品是POCT快速诊断检测试剂(胶体金)、时间分辨免疫荧光检测试剂、生化诊断检测试剂、化学发光检测试剂、生物原料系列、免疫印迹系列、电子仪器系列、生物传感电化学系列、分子诊断系列。报告期内,公司新增授权专利/软件著作权共43项,其中发明专利4项;截至报告期末,公司累计获得授权专利/软件著作权293项,其中发明专利51项。
发行价格:
133.67
{"stockData":{"symbol":"688606","market":"SH","secType":"STK","nameCN":"奥泰生物","latestPrice":44.34,"timestamp":1794553200000,"preClose":45.25,"halted":0,"volume":300467,"delay":0,"changeRate":-0.0201,"floatShares":75654400,"shares":75654400,"eps":1.4981,"marketStatus":"已收盘","change":-0.91,"latestTime":"11-13 15:00:00","open":45.3,"high":45.83,"low":44.09,"amount":13471400,"amplitude":0.0385,"askPrice":44.48,"askSize":8,"bidPrice":44.34,"bidSize":1,"shortable":0,"etf":0,"ttmEps":1.4981,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":5,"adr":0,"adjPreClose":45.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1794533400000,1794540600000],[1794546000000,1794553200000]],"highLimit":49.78,"lowLimit":40.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":75654353,"isCdr":false,"pbRate":0.89,"roa":"--","peRate":29.59749,"roe":"2.14%","epsLYR":2.78,"committee":-0.268293,"marketValue":3355000000,"turnoverRate":0.004,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-11-16。","afterMarket":{"amount":8868,"volume":200,"close":44.34,"buyVolume":0,"sellVolume":200,"time":1794555237746,"indexStatus":"已收盘 11-13 15:30:00","preClose":45.25},"floatMarketCap":3355000000},"requestUrl":"/m/hq/s/688606/tweets","defaultTab":"tweets","newsList":[{"id":"2682829320","title":"股市必读:奥泰生物新发布《关于召开2026年第三次临时股东会的通知》","url":"https://stock-news.laohu8.com/highlight/detail?id=2682829320","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682829320?lang=zh_cn&edition=full","pubTime":"2026-11-09 04:57","pubTimestamp":1794171428,"startTime":"0","endTime":"0","summary":"公司公告汇总:奥泰生物于2026年11月6日召开董事会,提名高飞、赵华芳、陆维克为第四届董事会非独立董事候选人,郭芳、周亚力、陈善基为独立董事候选人,拟提交11月23日召开的2026年第三次临时股东会审议。2026年第三次临时股东会会议资料杭州奥泰生物技术股份有限公司将于2026年11月23日召开第三次临时股东会,审议董事会换届选举事项。任期自股东会审议通过之日起三年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900001425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681898727","title":"奥泰生物(688606)披露董事会换届选举议案,11月06日股价下跌0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681898727","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681898727?lang=zh_cn&edition=full","pubTime":"2026-11-06 23:37","pubTimestamp":1793979459,"startTime":"0","endTime":"0","summary":"截至2026年11月6日收盘,奥泰生物报收于45.91元,较前一交易日下跌0.86%,最新总市值为34.73亿元。该股当日开盘45.55元,最高46.41元,最低45.53元,成交额达1107.84万元,换手率为0.32%。近日,奥泰生物披露《关于召开2026年第三次临时股东会的通知》,公司将于2026年11月23日召开2026年第三次临时股东会,会议采取现场投票与网络投票相结合的方式,股权登记日为2026年11月16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600039155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680979237","title":"奥泰生物(688606)11月2日主力资金净卖出211.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680979237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680979237?lang=zh_cn&edition=full","pubTime":"2026-11-03 08:23","pubTimestamp":1793665429,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月2日收盘,奥泰生物报收于45.82元,上涨6.56%,换手率0.92%,成交量6940.0手,成交额3116.84万元。近5日资金流向一览见下表:奥泰生物融资融券信息显示,融资方面,当日融资买入121.61万元,融资偿还427.88万元,融资净偿还306.27万元。奥泰生物主营业务:体外诊断试剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300010319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680725922","title":"奥泰生物(688606)2026年三季报简析:净利润同比下降56.3%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2680725922","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680725922?lang=zh_cn&edition=full","pubTime":"2026-11-01 06:30","pubTimestamp":1793485847,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期奥泰生物发布2026年三季报。截至本报告期末,公司营业总收入6.13亿元,同比下降3.14%,归母净利润8295.21万元,同比下降56.3%。本报告期奥泰生物三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达39.15%。持有奥泰生物最多的基金为鹏华弘嘉混合A,目前规模为2.89亿元,最新净值2.5783,较上一交易日上涨0.07%,近一年下跌8.99%。本文数据来源于奥泰生物2026年三季报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110100001624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679924345","title":"奥泰生物(688606)披露2026年第三季度报告,10月30日股价下跌2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679924345","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679924345?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:59","pubTimestamp":1793372362,"startTime":"0","endTime":"0","summary":"本报告期利润总额32,603,833.95元,同比下降50.70%;年初至报告期末利润总额86,626,730.70元,同比下降60.31%。归属于上市公司股东的净利润本报告期为32,107,420.74元,同比下降44.45%;年初至报告期末为82,952,129.05元,同比下降56.30%。研发投入本报告期36,086,472.66元,同比增长38.68%;年初至报告期末96,471,228.58元,同比增长29.99%。总资产本报告期末为4,009,167,387.43元,较上年度末下降5.50%;归属于上市公司股东的所有者权益为3,761,288,401.68元,较上年度末下降4.69%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000058169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679294574","title":"奥泰生物(688606.SH)发布前三季度业绩,归母净利润8295万元,同比下降56.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679294574","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679294574?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:06","pubTimestamp":1793354794,"startTime":"0","endTime":"0","summary":"智通财经APP讯,奥泰生物(688606.SH)披露2026年第三季度报告,前三季度公司实现营收6.13亿元,同比下降3.14%;归母净利润8295万元,同比下降56.30%;扣非净利润6671万元,同比下降54.64%;基本每股收益1.08元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677198622","title":"奥泰生物(688606)10月21日主力资金净卖出56.18万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677198622","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677198622?lang=zh_cn&edition=full","pubTime":"2026-10-22 08:33","pubTimestamp":1792629197,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月21日收盘,奥泰生物报收于45.81元,下跌2.18%,换手率0.51%,成交量3865.0手,成交额1783.17万元。近5日资金流向一览见下表:奥泰生物融资融券信息显示,融资方面,当日融资买入269.97万元,融资偿还427.52万元,融资净偿还157.54万元。奥泰生物主营业务:体外诊断试剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200007058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367399","title":"股市必读:奥泰生物新发布《2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367399","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665367399?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:41","pubTimestamp":1788716468,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,奥泰生物报收于45.72元,上涨0.33%,换手率0.19%,成交量1444.0手,成交额661.31万元。公司公告汇总2026年第二次临时股东会会议资料杭州奥泰生物技术股份有限公司召开2026年第二次临时股东会,审议变更公司注册资本、修订《公司章程》并办理工商变更登记;修订《董事和高级管理人员薪酬管理制度》;使用剩余超募资金3,518.52万元永久补充流动资金。其中股份回购导致注册资本由79,280,855元减至75,654,353元,相关议案已获董事会审议通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665366693","title":"每周股票复盘:奥泰生物(688606)拟用3518.52万元补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2665366693","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665366693?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:39","pubTimestamp":1788637150,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,奥泰生物报收于45.72元,较上周的47.69元下跌4.13%。本周,奥泰生物8月31日盘中最高价报47.3元。本周关注点来自公司公告汇总:奥泰生物拟使用剩余超募资金3,518.52万元永久补充流动资金。公司公告汇总杭州奥泰生物技术股份有限公司召开2026年第二次临时股东会,审议变更公司注册资本、修订《公司章程》并办理工商变更登记;修订《董事和高级管理人员薪酬管理制度》;使用剩余超募资金3,518.52万元永久补充流动资金。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664387178","title":"奥泰生物净利连降1年半 2021上市超募12亿申万宏源保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2664387178","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664387178?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:53","pubTimestamp":1788508383,"startTime":"0","endTime":"0","summary":"中国经济网北京9月4日讯 奥泰生物 日前披露2026年半年度报告。报告期内,公司实现营业收入3.92亿元,同比减少8.77%;归属于上市公司股东的净利润5084.47万元,同比减少61.48%;归属于上市公司股东的扣除非经常性损益的净利润4177.24万元,同比减少61.83%;经营活动产生的现金流量净额5288.50万元,同比减少13.80%。 2023年6月3日,奥泰生物发布2022年年度权益分派实施公告。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/04/20260904589207.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/04/20260904589207.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260904/32360300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK1147","BK0028","000166","06806","BK0239","BK0276","BK0183","BK1564","IPOS","BK0012","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664680607","title":"股市必读:奥泰生物新发布《2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664680607","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664680607?lang=zh_cn&edition=full","pubTime":"2026-09-04 02:42","pubTimestamp":1788460933,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘,奥泰生物报收于45.57元,下跌1.13%,换手率0.22%,成交量1671.0手,成交额766.19万元。公司公告汇总2026年第二次临时股东会会议资料杭州奥泰生物技术股份有限公司召开2026年第二次临时股东会,审议变更公司注册资本、修订《公司章程》并办理工商变更登记;修订《董事和高级管理人员薪酬管理制度》;使用剩余超募资金3,518.52万元永久补充流动资金。其中股份回购导致注册资本由79,280,855元减至75,654,353元,相关议案已获董事会审议通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048109","title":"奥泰生物(688606)2026年中报简析:净利润同比下降61.48%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048109","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048109?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:17","pubTimestamp":1788041878,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期奥泰生物发布2026年中报。截至本报告期末,公司营业总收入3.92亿元,同比下降8.77%,归母净利润5084.47万元,同比下降61.48%。本报告期奥泰生物三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达64.57%。持有奥泰生物最多的基金为鹏华弘嘉混合A,目前规模为2.75亿元,最新净值2.7857,较上一交易日上涨0.53%,近一年下跌4.43%。本文数据来源于奥泰生物2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662912110","title":"奥泰生物(688606)披露董事和高级管理人员薪酬管理制度,8月28日股价上涨0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662912110","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662912110?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:40","pubTimestamp":1787928043,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘,奥泰生物报收于47.69元,较前一交易日上涨0.46%,最新总市值为36.08亿元。该股当日开盘48.0元,最高48.31元,最低47.08元,成交额达1476.55万元,换手率为0.41%。近日,杭州奥泰生物技术股份有限公司披露《董事和高级管理人员薪酬管理制度》。薪酬方案由董事会薪酬与考核委员会制定,董事薪酬由股东会决定,高级管理人员薪酬由董事会批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800055483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662906193","title":"图解奥泰生物中报:第二季度单季净利润同比下降55.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662906193","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662906193?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:19","pubTimestamp":1787912349,"startTime":"0","endTime":"0","summary":"证券之星消息,奥泰生物2026年中报显示,上半年度公司主营收入3.92亿元,同比下降8.77%;归母净利润5084.47万元,同比下降61.48%;扣非净利润4177.24万元,同比下降61.83%;其中2026年第二季度,公司单季度主营收入1.97亿元,同比下降11.11%;单季度归母净利润3145.04万元,同比下降55.58%;单季度扣非净利润2999.95万元,同比下降41.28%;负债率5.93%,投资收益-551.96万元,财务费用1966.03万元,毛利率53.09%。财报数据概要请见下图:本文数据来源于奥泰生物2026年中报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800043177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662830066","title":"奥泰生物(688606)6月30日股东户数0.56万户,较上期增加3.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662830066","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662830066?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:42","pubTimestamp":1787910167,"startTime":"0","endTime":"0","summary":"证券之星消息,近日奥泰生物披露,截至2026年6月30日公司股东户数为5587.0户,较3月31日增加205.0户,增幅为3.81%。在医疗器械行业个股中,奥泰生物股东户数低于行业平均水平,截至6月30日,医疗器械行业平均股东户数为2.12万户。从股价来看,2026年3月31日至2026年6月30日,奥泰生物区间跌幅为33.2%,在此期间股东户数增加205.0户,增幅为3.81%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800040827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659102176","title":"每周股票复盘:奥泰生物(688606)回购362万股已注销","url":"https://stock-news.laohu8.com/highlight/detail?id=2659102176","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659102176?lang=zh_cn&edition=full","pubTime":"2026-08-16 03:27","pubTimestamp":1786822031,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,奥泰生物报收于49.35元,较上周的46.39元上涨6.38%。本周,奥泰生物8月11日盘中最高价报52.02元。本周关注点公司公告汇总:奥泰生物累计回购3,626,502股,占总股本4.57%,已全部注销。公司公告汇总杭州奥泰生物技术股份有限公司于2026年2月6日审议通过股份回购方案,拟以超募资金通过集中竞价交易方式回购股份,用于减少注册资本。回购股份已于2026年8月13日在中国证券登记结算有限责任公司注销,公司总股本由79,280,855股减少至75,654,353股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600001045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659161465","title":"股市必读:奥泰生物新发布《关于股份回购实施结果暨股份变动的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659161465","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659161465?lang=zh_cn&edition=full","pubTime":"2026-08-14 02:22","pubTimestamp":1786645332,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘,奥泰生物报收于49.45元,上涨0.75%,换手率1.05%,成交量7962.0手,成交额3959.48万元。公司公告汇总:奥泰生物完成股份回购并注销3,626,502股,总股本由79,280,855股减至75,654,353股。公司公告汇总关于股份回购实施结果暨股份变动的公告杭州奥泰生物技术股份有限公司于2026年2月6日审议通过股份回购方案,拟以超募资金通过集中竞价交易方式回购股份,用于减少注册资本。本次回购未导致公司控制权变化,股权分布仍符合上市条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400001443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658373905","title":"奥泰生物(688606)披露股份回购实施结果暨股份变动公告,8月12日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658373905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658373905?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:28","pubTimestamp":1786544897,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,奥泰生物报收于49.08元,较前一交易日下跌1.62%,最新总市值为38.91亿元。近日,奥泰生物披露《关于股份回购实施结果暨股份变动的公告》。截至2026年8月11日,公司累计回购股份3,626,502股,占总股本4.57%,回购价格区间为41.88元/股至68.29元/股,实际使用资金198,870,973.10元。回购股份已于2026年8月13日在中国证券登记结算有限责任公司注销,公司总股本由79,280,855股减少至75,654,353股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656832720","title":"奥泰生物(688606)披露股份回购进展公告,8月3日股价上涨1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656832720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656832720?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:51","pubTimestamp":1785750685,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘,奥泰生物报收于45.29元,较前一交易日上涨1.46%,最新总市值为35.91亿元。公司于近日披露《关于股份回购进展公告》。公告显示,杭州奥泰生物技术股份有限公司于2026年1月22日披露股份回购方案,回购期限为2026年2月9日至2027年2月8日,拟回购金额为10,000万元至20,000万元,回购股份用于减少注册资本。2026年7月单月回购428,800股,支付资金18,872,812.49元。本次回购符合相关法规及方案规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300024903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656331953","title":"每周股票复盘:奥泰生物(688606)回购金额达1.84亿元,占总股本4.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656331953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656331953?lang=zh_cn&edition=full","pubTime":"2026-08-02 03:00","pubTimestamp":1785610835,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,奥泰生物报收于44.64元,较上周的41.95元上涨6.41%。本周,奥泰生物7月30日盘中最高价报44.9元。本周关注点公司公告汇总:累计回购股份3,317,502股,占公司总股本的4.18%,已支付金额183,887,330.18元公司公告汇总关于股份回购进展公告杭州奥泰生物技术股份有限公司于2026年1月22日披露股份回购方案,回购期限为2026年2月9日至2027年2月8日,拟回购金额为10,000万元至20,000万元,回购股份用于减少注册资本。2026年7月单月回购428,800股,支付资金18,872,812.49元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794697336980,"stockEarnings":[{"period":"1week","weight":-0.0342},{"period":"1month","weight":-0.0714},{"period":"3month","weight":-0.1015},{"period":"6month","weight":-0.1619},{"period":"1year","weight":-0.3575},{"period":"ytd","weight":-0.2915}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.0746},{"period":"6month","weight":-0.1212},{"period":"1year","weight":-0.0981},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州奥泰生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5674人(较上一季度增加1.56%)","perCapita":"13333股","listingDate":"2021-03-25","address":"浙江省杭州市钱塘区杭州经济技术开发区白杨街道银海街550号第3幢第4幢第5幢厂房","registeredCapital":"7565万元","survey":" 杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产与销售。公司的主要产品是POCT快速诊断检测试剂(胶体金)、时间分辨免疫荧光检测试剂、生化诊断检测试剂、化学发光检测试剂、生物原料系列、免疫印迹系列、电子仪器系列、生物传感电化学系列、分子诊断系列。报告期内,公司新增授权专利/软件著作权共43项,其中发明专利4项;截至报告期末,公司累计获得授权专利/软件著作权293项,其中发明专利51项。","listedPrice":133.67},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥泰生物,688606,奥泰生物股票,奥泰生物股票老虎,奥泰生物股票老虎国际,奥泰生物行情,奥泰生物股票行情,奥泰生物股价,奥泰生物股市,奥泰生物股票价格,奥泰生物股票交易,奥泰生物股票购买,奥泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}